News
KYKOY
16.00
NaN%
--
Kyowa Kirin Non-GAAP EPS of ¥103.26, revenue of ¥263.63B; reaffirms FY 2026 outlook
Seeking Alpha · 08/03 07:55
Eli Lilly, Regeneron named to FDA pilot program to boost US drug manufacturing
Seeking Alpha · 06/29 21:50
Kyowa Kirin reports Q1 results
Seeking Alpha · 05/07 09:43
Kyowa Kirin Co., Ltd. Reports Climb In Q1 Bottom Line
NASDAQ · 05/07 06:55
Ultragenyx falls as guidance trails consensus amid job cuts
Seeking Alpha · 02/13 19:42
Amgen, Kyowa Kirin End Collaboration On Atopic Dermatitis Drug Rocatinlimab
NASDAQ · 01/30 14:05
Kura Oncology rises following Jim Cramer comments
Seeking Alpha · 12/22/2025 17:01
Kura Oncology, Kyowa Kirin reveal Komsifti combo data for AML
Seeking Alpha · 12/08/2025 18:00
Kura Oncology wins FDA approval for leukemia drug
Seeking Alpha · 11/13/2025 15:28
Weekly Report: what happened at KYKOY last week (0908-0912)?
Weekly Report · 09/15/2025 11:23
Amgen, Kyowa Kirin announce long-term Phase 3 data for eczema drug
Seeking Alpha · 09/09/2025 11:08
Weekly Report: what happened at KYKOY last week (0901-0905)?
Weekly Report · 09/08/2025 11:25
Weekly Report: what happened at KYKOY last week (0825-0829)?
Weekly Report · 09/01/2025 11:20
Weekly Report: what happened at KYKOY last week (0818-0822)?
Weekly Report · 08/25/2025 11:32
More
Webull provides a variety of real-time KYKOY stock news. You can receive the latest news about Kyowa Hakko through multiple platforms. This information may help you make smarter investment decisions.
About KYKOY
Kyowa Kirin Co Ltd is a Japan-based company engaged in the manufacture and sale of medical drugs. The Company operates in Pharmaceuticals business segment. The Company engages in the research, development, manufacture, sale, and import & export of prescription pharmaceuticals. The Company has drug discovery technologies in antibody therapeutics and hematopoietic stem cell gene therapy. Its development pipeline includes AMG531 for aplastic anemia untreated with immunosuppressive therapy, KHK4083/AMG 451 for moderate to severe atopic dermatitis, KHK4083/AMG 451 for moderate to severe asthma, and KK2845 for acute myeloid leukemia and others. In addition, through its subsidiaries, the Company develops, manufactures, markets, and contracts out biosimilar pharmaceuticals, and engages in wholesale and retail sales and insurance agency business. The Company operates in Japan and overseas.